The latest LISAvienna newsletter is now available

With APEIRON Biologics, Vienna is celebrating the market approval of an innovative neuroblastoma immunotherapy in the EU area. What else is new in the biotechnology and medical device sectors, and associated fields in Vienna? We will keep you informed about these topics on our webpage, via Twitter, and ten times per year with a free newsletter.

The May newsletter was sent out to more than 3,700 interested parties today. We look forward to feedback and new registrations.

Aside from the winners of the first phase of the aws BoB – Best of Biotech Business Plan competition, we would like to make note of the start-up labs that the Vienna Business Agency will set up at the Vienna Biocenter. There is additional great news from the VBC – we report on APERION Biologics’ market approval, the issuing of the new Austrian State Prize for Digital Services to SCARLETRED, a difficult $ 45.5 million financing round by Arsanis, and positive Phase 1 data from Hookipa Biotech.

There are also a lot of exciting things happening at Muthgasse: Themis began the first global study with a Zika live vaccine, and TAmiRNA announced its collaboration with Biomedica.

In addition to awards for contextflow, SIMCharacters, and the University of Vienna, we would like to point out that mySugr has recently passed the magical 1 million app user mark. Also exciting is Vienna’s debut as the starting point for the new worldwide grapevine initiative, which has set the goal of solving interface problems in the eHealth sector.

As usual, the newsletter contains additional news, events, funding information, and the latest article from our collaboration with Chemiereport. Happy reading!

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)